## PRIOR AUTHORIZATION REQUEST FORM

## Medicare Part D Zykadia

Phone: 800-728-7947 Fax back to: 866-880-4532

The Scott & White Health Plan Pharmacy Department manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. Please note, any information left blank or illegible may delay the review process.

	Prescriber Name:	
Patient Name:	Supervising Physician:	
Member/Subscriber Number:	Fax:	Phone:
Date of Birth:	Office Contact:	
Group Number:	NPI:	State Lic ID:
Address:	Address:	
City, State ZIP:	City, State ZIP:	
Primary Phone:	Specialty/facility name (if applicable):	
Drug Name and Strength:		
Directions / SIG:		
Please attach any pertinent medical history or information following que	for this patient that may support apestions and sign.	pproval. Please answer the
Q1. Is the patient a NEW START to Zykadia therapy?		
Yes		
☐ No (describe Zykadia treatment history)		
Q2. What diagnosis is this drug being prescribed for (pick of	one)?	
☐ Treatment of metastatic non-small cell lung cancer (NS	SCLC)	
☐ Other		
Q3. Please provide ICD code(s) for diagnosis		
Q4. If using for the treatment of metastatic non-small cell lukinase (ALK)-positive?	ung cancer (NSCLC), is the patient	anaplastic lymphoma
☐ Yes ☐ No		
Q5. Is prescribing physician an oncologist?		
☐ Yes ☐ No		

## PRIOR AUTHORIZATION REQUEST FORM

## Medicare Part D Zykadia

Phone: 800-728-7947 Fax back to: 866-880-4532

The Scott & White Health Plan Pharmacy Department manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. Please note, any information left blank or illegible may delay the review process.

Patient Name:	Prescriber Name: Supervising Physician:
Q6. Additional Comments	
Prescriber Signature	Date

□ Expedited/Urgent - By checking this box and signing above, I certify that applying the standard review timeframe may seriously jeopardize the life or health of the enrollee or the enrollee's ability to regain maximum function

This telecopy transmission contains confidential information belonging to the sender that is legally privileged. This information is intended only for the use of the individual or entity named above. The authorized recipient of this information is prohibited from disclosing this information to any other party. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or action taken in reference to the contents of this document is strictly prohibited. If you have received this telecopy in error, please notify the sender immediately to arrange for the return of this document